APA (7th ed.) Citation

NJ, B., J, Z., L, K., T, P., L, P., T, W., . . . T, F. (2025). Subcutaneous daratumumab plus carfilzomib and dexamethasone (D-Kd) versus carfilzomib and dexamethasone (Kd) in patients with relapsed/refractory multiple myeloma who received previous daratumumab treatment: LYNX study. Leukemia & lymphoma, 66(14), 2685. https://doi.org/10.1080/10428194.2025.2561117

Chicago Style (17th ed.) Citation

NJ, Bahlis, et al. "Subcutaneous Daratumumab Plus Carfilzomib and Dexamethasone (D-Kd) Versus Carfilzomib and Dexamethasone (Kd) in Patients with Relapsed/refractory Multiple Myeloma Who Received Previous Daratumumab Treatment: LYNX Study." Leukemia & Lymphoma 66, no. 14 (2025): 2685. https://doi.org/10.1080/10428194.2025.2561117.

MLA (9th ed.) Citation

NJ, Bahlis, et al. "Subcutaneous Daratumumab Plus Carfilzomib and Dexamethasone (D-Kd) Versus Carfilzomib and Dexamethasone (Kd) in Patients with Relapsed/refractory Multiple Myeloma Who Received Previous Daratumumab Treatment: LYNX Study." Leukemia & Lymphoma, vol. 66, no. 14, 2025, p. 2685, https://doi.org/10.1080/10428194.2025.2561117.